

Krystexxa Order Form (pegloticase)

FAX TO: 817-472-7213

PATIENT INFORMATION

Patient Name: _____ DOB: _____ Phone: _____ Sex: M F Ht: _____ Wt: _____ lbs kg
 Primary Language: _____ Allergies: _____
 Patient Preferred Location: _____

<ICD 10 CODE REQUIRED> DIAGNOSIS & CLINICAL INFORMATION

ICD 10 Code (PROVIDE COMPLETE CODE)

M1A._____ 0 Chronic Gout, w/o Tophi
 M1A._____ 1 Chronic Gout, w/ Tophi
 Other: _____

Prescribing Information

It is recommended that the patient discontinue oral urate-lowering medications 2-3 days (up to one week) before starting Krystexxa.

Recent data suggests that patients may have improved outcomes when immunomodulators are taken with Krystexxa.

- The recommended dosage is Krystexxa 8 mg every two weeks, co-administered w/weekly methotrexate 15 mg orally.
- Krystexxa alone may be used in patients for whom methotrexate is contraindicated or not clinically appropriate.

REQUIRED: Demographics and Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.
LAB RESULTS: : G6PD, baseline uric acid > 6.0 mg/dL.

PRESCRIPTION

Pre-Medications

Required:

Acetaminophen: 650 mg PO, may repeat q 4-6 hours, PRN infusion reaction
 Diphenhydramine: 25 mg IVP, may repeat q 6 hours, PRN infusion reaction
 Methylprednisolone: 125 mg SIVP
 Other: _____

Lab Orders+

Required: Uric Acid Level, 24-72 hours prior to infusion
 If Uric Acid Level > 6 mg/dL upon two consecutive lab draws, hold dose, and contact prescriber

+Medix Infusion will draw maintenance labs unless otherwise directed by Referring Provider

KRYSTEXXA (pegloticase)

Loading Dose

IV: Infuse 8 mg in 250 mL of 0.9% Sodium Chloride over 2 hours, every 2 weeks for one year

Is the patient on any other disease modifying therapy? Yes No
 If yes, please note therapy and last dose: _____

Post Treatment Observations: The patient is observed for 60 minutes following each infusion.

Adverse Events: In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.

PRESCRIBER INFORMATION

Prescriber Name: _____ Signature: _____
 Date: _____ NPI #: _____ Specialty: _____
 Supervising Physician: _____ (If Applicable)
 Address: _____ City: _____ State: _____ Zip: _____
 Contact Name: _____ Phone: _____ Fax: _____ Email: _____